Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threate... Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms. Show more
Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
Nes-Ziona, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
Nes-Ziona, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.075 | -6.14754098361 | 1.22 | 1.27 | 1.145 | 117570 | 1.2293092 | CS |
4 | -0.0852 | -6.9257031377 | 1.2302 | 1.27 | 1.12 | 124428 | 1.20462212 | CS |
12 | -0.535 | -31.8452380952 | 1.68 | 1.71 | 0.8101 | 254937 | 1.25134191 | CS |
26 | -0.205 | -15.1851851852 | 1.35 | 1.75 | 0.8101 | 154149 | 1.31607216 | CS |
52 | -2.135 | -65.0914634146 | 3.28 | 4.59 | 0.8101 | 139406 | 1.7299262 | CS |
156 | -4.755 | -80.593220339 | 5.9 | 8.64 | 0.8101 | 76462 | 2.65820139 | CS |
260 | -7.455 | -86.6860465116 | 8.6 | 29.4 | 0.8101 | 176628 | 8.89646998 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions